文献速递泌尿男性生殖肿瘤

根治性膀胱切除术与三联疗法治疗肌层浸润性膀胱癌:多机构倾向评分匹配与加权分析

Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
PubMed 文献 · Lancet Oncol · 2023-05-12

这项回顾性多机构分析纳入722例临床T2-T4N0M0肌层浸润性膀胱尿路上皮癌患者(440例根治性膀胱切除术,282例三联疗法),采用倾向评分匹配和加权比较生存结局。在匹配和加权分析中,无转移生存、癌症特异性生存和无病生存无显著差异,总生存 favored 三联疗法。作者认为三联疗法在多学科共享决策下应提供给所有合适候选者。

要点

  • 匹配后5年无转移生存:根治性膀胱切除术74% vs 三联疗法75%(IPTW),74% vs 74%(PSM),均无显著差异。
  • 总生存 favored 三联疗法:IPTW HR 0.70(95%CI 0.53-0.92;p=0.010),PSM HR 0.75(0.58-0.97;p=0.0078)。
  • 三联疗法组38例(13%)行挽救性膀胱切除术。

核心结论

  • 在选择性肌层浸润性膀胱癌患者中,根治性膀胱切除术与三联疗法的肿瘤学结局相似。
  • 作者认为这些结果支持在多学科共享决策下,三联疗法应提供给所有合适候选者,而不仅限于有严重合并症无法手术的患者。

研究设计与样本

  • 回顾性分析纳入722例临床T2-T4N0M0肌层浸润性膀胱尿路上皮癌患者(440例根治性膀胱切除术,282例三联疗法),均符合两种治疗条件。
  • 患者来自美国和加拿大三个大学中心,治疗时间为2005年1月1日至2017年12月31日。
  • 所有患者为单发肿瘤小于7 cm,无或单侧肾积水,无广泛或多灶性原位癌。
  • 440例根治性膀胱切除术占贡献机构研究期间所有根治性膀胱切除术的29%。
  • 采用倾向评分匹配(3:1匹配,有放回)和逆概率治疗加权(IPTW)分析生存差异。

主要发现

  • PSM分析中3:1匹配队列共1119例(837例根治性膀胱切除术,282例三联疗法)。
  • 匹配后两组年龄(根治性膀胱切除术71.4岁[IQR 66.0-77.1] vs 三联疗法71.6岁[64.0-78.9])、性别(女性213例[25%] vs 68例[24%];男性624例[75%] vs 214例[76%])等基线相似。
  • 5年无转移生存:IPTW下根治性膀胱切除术74%(95%CI 70-78)vs 三联疗法75%(70-80);PSM下74%(70-77)vs 74%(68-79)。
  • 无转移生存无差异:IPTW SHR 0.89(95%CI 0.67-1.20;p=0.40),PSM SHR 0.93(0.71-1.24;p=0.64)。
  • 5年癌症特异性生存:IPTW下根治性膀胱切除术81%(77-85)vs 三联疗法84%(79-89);PSM下83%(80-86)vs 85%(80-89),均无显著差异(IPTW SHR 0.72[0.50-1.04];p=0.071;PSM SHR 0.73[0.52-1.02];p=0.057)。

关键数值与推荐

  • 5年无病生存:IPTW下根治性膀胱切除术73%(95%CI 69-77)vs 三联疗法74%(69-79);PSM下76%(72-80)vs 76%(71-81)。
  • 无病生存无差异:IPTW SHR 0.87(95%CI 0.65-1.16;p=0.35),PSM SHR 0.88(0.67-1.16;p=0.37)。
  • 总生存 favored 三联疗法:IPTW下根治性膀胱切除术66%(95%CI 61-71)vs 三联疗法73%(68-78),HR 0.70(0.53-0.92;p=0.010);PSM下72%(69-75)vs 77%(72-81),HR 0.75(0.58-0.97;p=0.0078)。
  • 各中心间癌症特异性生存和无转移生存无统计学差异(p=0.22-0.90)。
  • 440例根治性膀胱切除术患者病理分期:pT2 124例(28%),pT3-4 194例(44%),淋巴结阳性114例(26%);中位淋巴结切除数39枚,软组织切缘阳性率1%(n=5),围手术期死亡率2.5%(n=11)。

临床怎么用

  • 作者认为,在多学科共享决策下,三联疗法应提供给所有合适的肌层浸润性膀胱癌候选者,而不仅限于有严重合并症无法手术的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous randomised controlled trials comparing bladder preservation with radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accrual. Given that no further trials are foreseen, we aimed to use propensity scores to compare trimodality therapy (maximal transurethral resection of bladder tumour followed by concurrent chemoradiation) with radical cystectomy. METHODS: This retrospective analysis included 722 patients with clinical stage T2-T4N0M0 muscle-invasive urothelial carcinoma of the bladder (440 underwent radical cystectomy, 282 received trimodality therapy) who would have been eligible for both approaches, treated at three university centres in the USA and Canada between Jan 1, 2005, and Dec 31, 2017. All patients had solitary tumours less than 7 cm, no or unilateral hydronephrosis, and no extensive or multifocal carcinoma in situ. The 440 cases of radical cystectomy represent 29% of all radical cystectomies performed during the study period at the contributing institutions. The primary endpoint was metastasis-free survival. Secondary endpoints included overall survival, cancer-specific survival, and disease-free survival. Differences in survival outcomes by treatment were analysed using propensity scores incorporated in propensity score matching (PSM) using logistic regression and 3:1 matching with replacement and inverse probability treatment weighting (IPTW). FINDINGS: In the PSM analysis, the 3:1 matched cohort comprised 1119 patients (837 radical cystectomy, 282 trimodality therapy). After matching, age (71·4 years [IQR 66·0-77·1] for radical cystectomy vs 71·6 years [64·0-78·9] for trimodality therapy), sex (213 [25%] vs 68 [24%] female; 624 [75%] vs 214 [76%] male), cT2 stage (755 [90%] vs 255 [90%]), presence of hydronephrosis (97 [12%] vs 27 [10%]), and receipt of neoadjuvant or adjuvant chemotherapy (492 [59%] vs 159 [56%]) were similar between groups. Median follow-up was 4·38 years (IQR 1·6-6·7) versus 4·88 years (2·8-7·7), respectively. 5-year metastasis-free survival was 74% (95% CI 70-78) for radical cystectomy and 75% (70-80) for trimodality therapy with IPTW and 74% (70-77) and 74% (68-79) with PSM. There was no difference in metastasis-free survival either with IPTW (subdistribution hazard ratio [SHR] 0·89 [95% CI 0·67-1·20]; p=0·40) or PSM (SHR 0·93 [0·71-1·24]; p=0·64). 5-year cancer-specific survival for radical cystectomy versus trimodality therapy was 81% (95% CI 77-85) versus 84% (79-89) with IPTW and 83% (80-86) versus 85% (80-89) with PSM. 5-year disease-free survival was 73% (95% CI 69-77) versus 74% (69-79) with IPTW and 76% (72-80) versus 76% (71-81) with PSM. There were no differences in cancer-specific survival (IPTW: SHR 0·72 [95% CI 0·50-1·04]; p=0·071; PSM: SHR 0·73 [0·52-1·02]; p=0·057) and disease-free survival (IPTW: SHR 0·87 [0·65-1·16]; p=0·35; PSM: SHR 0·88 [0·67-1·16]; p=0·37) between radical cystectomy and trimodality therapy. Overall survival favoured trimodality therapy (IPTW: 66% [95% CI 61-71] vs 73% [68-78]; hazard ratio [HR] 0·70 [95% CI 0·53-0·92]; p=0·010; PSM: 72% [69-75] vs 77% [72-81]; HR 0·75 [0·58-0·97]; p=0·0078). Outcomes for radical cystectomy and trimodality therapy were not statistically different among centres for cancer-specific survival and metastasis-free survival (p=0·22-0·90). Salvage cystectomy was done in 38 (13%) trimodality therapy patients. Pathological stage in the 440 radical cystectomy patients was pT2 in 124 (28%), pT3-4 in 194 (44%), and 114 (26%) node positive. The median number of nodes removed was 39, the soft tissue positive margin rate was 1% (n=5), and the perioperative mortality rate was 2·5% (n=11). INTERPRETATION: This multi-institutional study provides the best evidence to date showing similar oncological outcomes between radical cystectomy and trimodality therapy for select patients with muscle-invasive bladder cancer. These results support that trimodality therapy, in the setting of multidisciplinary shared decision making, should be offered to all suitable candidates with muscle-invasive bladder cancer and not only to patients with significant comorbidities for whom surgery is not an option. FUNDING: Sinai Health Foundation, Princess Margaret Cancer Foundation, Massachusetts General Hospital.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zlotta AR, Ballas LK, Niemierko A, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023. PMID: 37187202. doi:10.1016/S1470-2045(23)00170-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。